

When to Start and Stop the Inotropic Drugs in Cardiac Surgery?

Alessandro Belletti, Marcello Guarnieri and Elena Bignami*

Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy

*Corresponding author: Elena Bignami, Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132 Milan, Italy, E-mail: bignami.elena@hsr.it

Received date: April 18, 2016; Accepted date: May 18, 2016; Published date: May 26, 2016

Copyright: © 2016 Belletti A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Short Communication

All cardiac anesthesiologists are familiar with inotropes and vasopressors, as patients undergoing cardiac surgery frequently require administration of these drugs during the perioperative period. Surgery of the heart can now be conducted without cardioplegia and cardiopulmonary bypass (CPB), and even percutaneously (e.g. transcatheter aortic valve implantation-TAVI), patients have by definition a pre-operative severe cardiac disease, which increases the risk of post-operative hemodynamic instability. Ventricular function declines in the first hours following cardiac surgery in almost every patient, regardless of type of operation [1], not to mention the critical phase of weaning from CPB. Therefore, cardiac anesthesiologists must often balance the need for maintaining adequate cardiac output (CO) and organ perfusion to achieve successful CPB weaning and help the patient overcoming first few hours of post-operative period, with the well-described side effects of currently available inotropes and vasopressors [1]. Of note, side effects of inotropes and vasoconstrictors include development of tachyarrhythmias and increased myocardial oxygen consumption, which might become particularly relevant in patients with an already compromised myocardial function.

Despite being so widely used, several surveys and studies highlighted a large inter- and intra-center variability in use of inotropes in adult and pediatric cardiac surgery, both in frequency of administration and in choice of first-line agents [2-4]. Furthermore, observational studies have suggested that inotropes use may increase mortality, although this finding does not seem to find confirmation in randomized clinical trials (RCTs) [5].

In such a context, implementation of evidence-based recommendations may be of great help for physicians and improve outcome, as occurred after the development of Surviving Sepsis Campaign guidelines [6].

Unfortunately, available evidence on inotropes use after cardiac surgery is weak [7]. Although a consistent number of RCTs have been performed, only few were adequately designed to investigate clinically relevant outcomes, such as mortality [7], even though the call for high-quality evidence dates back to the late '80s [7].

Furthermore, post-operative pathophysiology might be very different between patients depending on the pre-operative cardiac disease. For example, variation in heart rate and rhythm, preload, afterload or ventricular compliance may be very differently tolerated if the heart was chronically ischemic, pressure-overloaded or volume-overloaded, and management should vary accordingly, thus making development of guidelines and design of RCTs particularly difficult. An objective quantification of inotropic support may thus be of help both for clinicians and researchers, allowing stratification of disease severity and prognosis. The Vasoactive-Inotropic Score (VIS) currently derived

and validated only for pediatric cardiac surgery [8], is a simple tool which could be more extensively applied also to adult patients.

Timing of initiation and suspension of inotropes and vasopressors is also critical, as an unnecessary administration exposes the patient to side effects without providing benefits, while waiting too long before initiating hemodynamic support may lead to end-organ damage. Therefore, accurate and comprehensive monitoring of hemodynamic parameters and perfusion indices has a pivotal role. Is thus not surprising that also in this setting goal-directed perioperative hemodynamic optimization showed promising results [9], although the efficacy of standardized protocols in intensive care unit (ICU), particularly concerning hemodynamic management, is a matter of debate [9]. It is worth noting that, while several studies addressed the question of when to start inotropic treatment, nobody focused on determining when treatment has been successful and is appropriate to interrupt vasoactive administration.

Besides pharmacologic support, perioperative hemodynamic management include also optimization of volume status and pacing, transfusion and, if necessary, institution of mechanical circulatory support (which can range from intra-aortic balloon pump [IABP] to full cardiopulmonary support with extra-corporeal membrane oxygenation [ECMO]). Unfortunately, all of these issues are subject to controversies and debate (perioperative fluid administration is a clear example).

However, despite all these limitations, guidelines on post-operative intensive care management of cardiac surgery patients have been developed in Germany and have been helpful in changing clinical practice [10].

We believe that recommendations from world-renowned experts, based on available evidence, should be developed for perioperative hemodynamic management of cardiac surgery patients.

References

1. St Andre AC, DelRossi A (2005) Hemodynamic management of patients in the first 24 hours after cardiac surgery. *Crit Care Med* 33: 2082-2093.
2. Bignami E, Belletti A, Moliterni P, Frati E, Guarnieri M, et al. (2016) Clinical practice in perioperative monitoring in adult cardiac surgery: is there a standard of care? Results from a national survey. *J Clin Monit Comput* 30: 347-365.
3. Bastien O, Vallet B (2005) French multicentre survey on the use of inotropes after cardiac surgery. *Crit Care* 9: 241-242.
4. Rizza A, Bignami E, Belletti A, Polito A, Ricci Z, et al. (2016) Vasoactive Drugs and Hemodynamic Monitoring in Pediatric Cardiac Intensive Care: An Italian Survey. *World J Pediatr Congenit Heart Surg* 7: 25-31.
5. Belletti A, Castro ML, Silveti S, Greco T, Biondi-Zoccai G, et al. (2015) The effect of inotropes and vasopressors on mortality: a meta-analysis of randomized clinical trials. *Br J Anaesth* 115: 656-675

-
6. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, et al. (2013) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. *Intensive Care Med* 39: 165-228.
 7. Gillies M, Bellomo R, Doolan L, Buxton B (2005) Bench-to-bedside review: Inotropic drug therapy after adult cardiac surgery -- a systematic literature review. *Crit Care* 9: 266-279.
 8. Gaies MG, Gurney JG, Yen AH, Napoli ML, Gajarski RJ, et al. (2010) Vasoactive-inotropic score as a predictor of morbidity and mortality in infants after cardiopulmonary bypass. *Pediatr Crit Care Med* 11: 234-238.
 9. Osawa EA, Rhodes A, Landoni G, Galas FR, Fukushima JT, et al. (2016) Effect of Perioperative Goal-Directed Hemodynamic Resuscitation Therapy on Outcomes Following Cardiac Surgery: A Randomized Clinical Trial and Systematic Review. *Crit Care Med* 44: 724-733.
 10. Kastrup M, Carl M, Spies C, Sander M, Markewitz A, et al. (2013) Clinical impact of the publication of S3 guidelines for intensive care in cardiac surgery patients in Germany: results from a postal survey. *Acta Anaesthesiol Scand* 57: 206-213.